Clinical trials
Glucose Intolerance trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 4 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| IRCCS San Raffaele | 3 |
| Azienda Ospedaliero, Universitaria Pisana | 2 |
| University of Messina | 2 |
| University of Pisa | 2 |
| Azienda Ospedaliero-Universitaria di Parma | 1 |
| Catholic University of the Sacred Heart | 1 |
| Federico II University | 1 |
| Fondazione IRCCS Policlinico San Matteo di Pavia | 1 |
| Fondazione per la ricerca sulla Fibrosi Cistica | 1 |
| ICE S.p.A. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glucose Intolerance | 22 |
| Diabetes Mellitus, Type 2 | 8 |
| Insulin Resistance | 5 |
| Metabolic Syndrome | 4 |
| Obesity | 3 |
| Cardiovascular Diseases | 2 |
| Cystic Fibrosis | 2 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Type 1 | 2 |
| Hyperglycemia | 2 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.